The role of intermittent androgen deprivation in prostate cancer

BJU International

Volumn 100, Issue 4, 2007, Pages 738-743

  Boccon Gibod, Laurent ^a   Hammerer, Peter ^b   Madersbacher, Stephan ^c   Mottet, Nicolas ^d   Prayer Galetti, Tommaso ^e   Tunn, Ulf ^f  

^a BICHAT HOSPITAL   (France)

^b Academic Hospital   (Germany)

^c Department of Animal Breeding and Reproduction   (Austria)

^d Clinique Mutualiste   (France)

^e UNIVERSITY OF PADOVA   (Italy)

^f Academic Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

BONE DENSITY; CANCER CELL; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COGNITION; COST BENEFIT ANALYSIS; DISEASE COURSE; HORMONAL THERAPY; HUMAN; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SHORT SURVEY;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 34548443017     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07053.x     Document Type: Short Survey

References (40)

1. Smith MR. Complementary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am 2001 15 : 559 71
2. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003 8 : 474 87
3. Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004 9 : 295 301
4. Higano CS. Side-effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003 61 (Suppl. 2A 32 9
5. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006 24 : 3979 83
6. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990 50 : 2275 82
7. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995 28 : 273 83
8. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993 71 : 2782 90
9. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor Volume and endocrine and growth factors. Cancer Res 1992 52 : 1598 605
10. Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005 75 : 204 8
11. Albrecht W, Collette L, Fava C et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003 44 : 505 11
12. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004 64 : 1182 6
13. Otto SJ, Schroder FH, de Koning HJ. Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial. J Clin Oncol 2006 24 : 4184 9
14. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003 170 : 1808 11
15. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004 29 : 1071 81
16. Spry NA, Kristjanson L, Hooton B et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006 42 : 1083 92
17. Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000 38 : 543 9
18. Da Silva FC, Gonçalves F, Santos A et al. Phase III study intermittent monotherapy versus continuous combined androgen deprivation: an international cooperative study. J Urol 2005 173 (Suppl. 220, Abstract 813
19. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986 58 : 2546 50
20. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995 45 : 839 44
21. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996 48 : 800 4
22. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996 30 (Suppl. 1 22 5
23. Oliver RT, Williams G, Paris AM, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997 49 : 79 82
24. Theyer G, Holub S, Durer A et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer 1997 75 : 1510 8
25. Horwich A, Huddart RA, Gadd J et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998 81 : 96 9
26. Bruchovsky N, Klotz L, Crook J et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006 107 : 389 95
27. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999 53 : 530 4
28. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients. factors predictive of prolonged time off therapy. Oncologist 2000 5 : 45 52
29. Sato N, Akakura K, Isaka S et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004 64 : 341 5
30. Peyromaure M, Delongchamps NB, Debre B, Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 2005 65 : 724 9
31. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation. update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001 58 : 240 5
32. De La Taille A, Zerbib M, Conquy S et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003 91 : 18 22
33. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007 99 (Suppl. 1 19 22
34. Shaw GL. International study of the intermittent treatment of cancer of the prostate. Proceedings of the International Study of Intermittent Therapy for Cancer of the Prostate (ISICAP) Meeting, Vancouver, Canada, March 2006. Ann Oncol 2005 169 (Suppl. 2 Abstract 88
35. Da Silva FC, Bono A, Whelan P et al. Phase III study of intermittent MAB versus continuous MAB - an international cooperative study - quality of life. Eur Urol 2006 5 : 289, Abstract 1066
36. Yamanaka H, Ito K, Naito S et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 2005 63 : 56 64
37. Gulley JLJL, Figg WD, Steinberg SM et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005 173 : 1567 71
38. Tunn U, Kurek R, Keinle E et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy. J Urol 2004 171 : 384, Abstract 1458
39. Collette L, Studer UE, Whelan P et al. Is the degree of PSA decline after immediate androgen deprivation a prognostic factor for outcome in patients with T0-4, N0, M0 prostate cancer not suitable for local treatment with curative intent? (Results from the EORTC 30891 trial). Eur Urol 2006 5 : 288, Abstract 1062
40. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 7 : 472 9